Zacks: Aytu Bioscience Inc (NASDAQ:AYTU) Given Average Rating of “Strong Buy” by Brokerages

Aytu Bioscience Inc (NASDAQ:AYTU) has received an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus target price of $4.88 for the company and are anticipating that the company will post ($0.34) EPS for the current quarter, according to Zacks. Zacks has also given Aytu Bioscience an industry rank of 93 out of 255 based on the ratings given to its competitors.

AYTU has been the subject of a number of analyst reports. ValuEngine lowered Aytu Bioscience from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Northland Securities began coverage on Aytu Bioscience in a research note on Friday, November 15th. They issued a “buy” rating and a $5.00 price target for the company. Finally, Zacks Investment Research upgraded Aytu Bioscience from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Wednesday, February 19th.

In other news, major shareholder Armistice Capital Master Fund acquired 78,788 shares of Aytu Bioscience stock in a transaction on Friday, December 20th. The shares were acquired at an average price of $0.90 per share, with a total value of $70,909.20. Also, CEO Joshua R. Disbrow acquired 55,000 shares of Aytu Bioscience stock in a transaction on Thursday, December 19th. The stock was purchased at an average cost of $0.83 per share, for a total transaction of $45,650.00. Insiders own 5.80% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Searle & CO. increased its stake in Aytu Bioscience by 9.0% in the 4th quarter. Searle & CO. now owns 272,437 shares of the company’s stock worth $265,000 after acquiring an additional 22,589 shares during the last quarter. Virtu Financial LLC bought a new stake in Aytu Bioscience in the 3rd quarter worth approximately $36,000. Finally, BlackRock Inc. bought a new stake in Aytu Bioscience in the 2nd quarter worth approximately $36,000. 40.83% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:AYTU opened at $0.55 on Tuesday. Aytu Bioscience has a fifty-two week low of $0.50 and a fifty-two week high of $2.61. The company has a debt-to-equity ratio of 1.37, a current ratio of 1.15 and a quick ratio of 0.99. The business has a 50 day moving average price of $0.76 and a 200-day moving average price of $1.02.

About Aytu Bioscience

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

Read More: Why do earnings reports matter?

Get a free copy of the Zacks research report on Aytu Bioscience (AYTU)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with's FREE daily email newsletter.